Recently, ATF6 has also been proposed as a predictor of bortezomib sensitivity in MM cells since drug resistance evolves to reduce cellular dependence on the UPR by downregulation of ATF6 and XBP1 expression [62]. This evidence concerns the gene XBP1 and Miyoshi myopathy.